Vivoryon Therapeutics N.V. · EURONEXT:VVY

Vivoryon Therapeutics — Investor Presentation (December 2021)

17 slides from Vivoryon Therapeutics's investor presentation, December 2021

  1. Slide 1: Tackling AD at the roots: early intervention to address multiple hallmarks of AD

    Tackling AD at the roots: early intervention to address multiple hallmarks of AD |Vivoryon Therapeutics N.V. - December 2021

  2. Slide 2: Important Notice and Disclaimer

    IMPORTANT NOTICE AND DISCLAIMER This Presentation has been prepared and issued by Vivoryon Therapeutics N.V. (the “Company”) and has not been independently verified by any third party. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed

  3. Slide 3: Vivoryon Therapeutics Overview

    VIVORYON THERAPEUTICS Overview Enzyme inhibition for targeted intervention: Modulating the activity of proteins altered in disease settings Lead product candidate varoglutamstat in AD: Phase 2a evidence of disease-modifying activity Statistically significant improvement in working memory after 3-mon

  4. Slide 4: Experienced Leadership

    EXPERIENCED LEADERSHIP Seasoned Biopharma Experts Covering All Relevant Aspects of Drug Development MANAGEMENT NON-EXECUTIVE DIRECTORS Ulrich Dauer, PhD Erich Platzer, MD Chief Executive Officer, Executive Director Chairman Dinnies Johannes von der Osten, PhD Vice Chairman Michael Schaeffer, PhD Chi

  5. Slide 5: Diverse Pipeline Addressing Severe Indications

    DIVERSE PIPELINE ADDRESSING SEVERE INDICATIONS Program Approach Discovery Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Status Varoglutamstat SMI Ongoing; Interim safety mid-2022; (PQ912) QPCT/L VIVIAD - Ph2b in EU Final readout H2-2023 Ph 2a ongoing; Stage-gate decision to Varoglutamstat SMI (PQ912

  6. Slide 6: Alzheimer's Disease: The Burden and a Path Forward

    ALZHEIMER’S DISEASE THE BURDEN A PATH FORWARD ~30 million people suffering from AD VVY discovered QPCT-mediated formation of a neurotoxic Abeta variant, worldwide, number expected to double by N3pE amyloid (pGlu-Abeta), as driver of AD pathology1,2 2050, with ~12.7 million in the US alone VVY is dev

  7. Slide 7: Drug Development in Alzheimer's Disease

    DRUG DEVELOPMENT IN ALZHEIMER’S DISEASE THE CHALLENGE Low success rate and long development phase delay new treatments and discourage investment in AD drug development Studies across drug development programs have identified important strategies for decreasing the risk and increasing the likelihood

  8. Slide 8: Targeting QPCT/L in AD

    TARGETING QPCT/L IN AD Validated Target for Intervention Upstream of Pathological Processes ROLE OF QPCT/L IN AD PATHOLOGY NEUROTOXIC N3PE DRIVES AD PATHOLOGY CCL2 Increased activity of glutaminyl cyclase (QPCT) is Abeta upregulated in AD associated with AD pathology1 Varoglutamstat QPCT catalyzes f

  9. Slide 9: Therapeutic Interventions in AD

    THERAPEUTIC INTERVENTIONS IN AD Varoglutamstat Inhibits Formation of Toxic Abeta Species Upstream of Other Approaches ROLE OF QPCT/L IN AD PATHOLOGY VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS CCL2 Increased activity of glutaminyl cyclase (QPCT) is Abeta upregulated in AD associated with AD patholo

  10. Slide 10: Varoglutamstat: Potential to Alter the Course of AD

    VAROGLUTAMSTAT: POTENTIAL TO ALTER THE COURSE OF AD Translating in vivo Evidence for Relevance of QPCT Inhibition into Human AD Abeta Pathology QPCT is essential for N3pE amyloid formation in vivo1 Dose-dependent reduction of QPCT 5XFAD mice, QPCT ko and tg QPCT/ N3pE activity in CSF & serum (Ph1 +

  11. Slide 11: Clinical Development Strategy

    CLINICAL DEVELOPMENT STRATEGY Clear Path To Regulatory Approval with Upside Potential for Accelerated Approval Pivotal study or accelerated approval Two possible scenarios Phase 2b VIVIAD Safety, tolerability and efficacy in 250 § Application for accelerated Patients MCI and mild AD approval (based

  12. Slide 12: SAPHIR – Guiding Phase 2b Trial Design

    SAPHIR– GUIDING PHASE 2B TRIAL DESIGN COGNITION INFORMED TRIAL DESIGN OF EU PHASE 2B Significant improvement of a working memory parameter SIGNIFICANT EFFECTS IN PHASE 2A DOSING within 3 months (One Back Test ) CCL2 DLT reached at 800 mg; reported AEs mostly mild to Meaningful trend towards improvem

  13. Slide 13: Multiple Avenues to Value Generation

    MULTIPLE AVENUES TO VALUE GENERATION Diverse Pipeline of Oral Small Molecule Inhibitors to Address Exceptionally High Medical Need ALZHEIMER‘S DISEASE INFLAMMATION/NASH Small molecule oral QPCT/L inhibitors with good Small molecule QPCTL inhibitors to modulate the blood-brain barrier penetration CCL

  14. Slide 14: QPCTL Inhibition in Cancer

    QPCTL INHIBITION IN CANCER Opportunity to Develop Oral Small Molecule Inhibitors in Immuno-Oncology BACKGROUND OPPORTUNITY Large unmet medical need remains to effectively and safely Orally administered small molecule approach: no antigen sink treat cancer patients effect, potential for improved tumo

  15. Slide 15: QPCTL Inhibition in Inflammation/NASH

    QPCTL INHIBITION IN INFLAMMATION/NASH Opportunity to Develop Oral Small Molecule Inhibitors in Inflammatory Kidney and Liver Diseases BACKGROUND OPPORTUNITY Non-alcoholic fatty liver disease (NAFLD) is a chronic hepatic First-in-class orally available compounds targeting a subclass of disorder chara

  16. Slide 16: Meprin Inhibition in AKI/CKD

    MEPRIN INHIBITION IN AKI/CKD Opportunity to Develop Oral Small Molecule Inhibitors In Fibrosis and Kidney Diseases BACKGROUND OPPORTUNITY The estimated incidence rate of acute kidney injury (AKI) during First-in-class orally available picomolar small molecule hospitalization in the US is 2-5%, it ar

  17. Slide 17: Vivoryon Therapeutics N.V. Contact

    Vivoryon Therapeutics N.V. Munich Franz-Josef-Delonge-Str. 5 81249 München Germany Halle (Saale) Weinbergweg 22 06120 Halle (Saale) Germany info@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com

Vivoryon Therapeutics — Investor Presentation (December 2021) on 6ix